NASDAQ:SPRO Spero Therapeutics Q3 2026 Earnings Date & Estimates $1.12 -0.03 (-2.61%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.16 +0.04 (+3.57%) As of 10/14/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Spero Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Spero Therapeutics in Q3 2026Spero Therapeutics is expected to post earnings of -$0.14 per share. In the same quarter a year earlier Spero Therapeutics reported -$0.13 per share on revenue of $5.44 million. Spero Therapeutics last reported on August 12, 2026, posting -$0.16 per share and beating the -$0.17 consensus estimate. Spero Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.14Prior-Year EPS-$0.13Prior-Year Revenue$5.44 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.16 (Beat by +$0.01)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Spero Therapeutics Q3 2026 Earnings FAQ When does Spero Therapeutics report Q3 2026 earnings? Spero Therapeutics (NASDAQ:SPRO) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Spero Therapeutics' Q3 2026 earnings call? Spero Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Spero Therapeutics? Analysts expect Spero Therapeutics to post earnings of -$0.14 per share for Q3 2026. Spero Therapeutics Earnings HeadlinesSpero Therapeutics (NASDAQ:SPRO) Shares Break Below 200-Day Moving Average - What's Next?October 13 at 2:21 AM | americanbankingnews.comSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Spero Therapeutics consensus price target raised 25% to $5.10October 2, 2026 | msn.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comSpero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comSee More Spero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spero Therapeutics and other key companies, straight to your email. Email Address About Spero TherapeuticsSpero Therapeutics (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company focused on developing treatments for serious bacterial infections and other infectious diseases. The company’s research programs are aimed at addressing drug-resistant pathogens and conditions for which existing therapies may be limited. Spero’s pipeline has included tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The company has also developed SPR720, an oral antibiotic candidate intended for the treatment of nontuberculous mycobacterial pulmonary disease, and SPR206, an intravenous antibiotic candidate targeting serious infections caused by multidrug-resistant Gram-negative bacteria. Founded in 2013 and headquartered in Cambridge, Massachusetts, Spero conducts its development activities primarily through clinical research and collaborations with industry and research partners. Its programs are designed for patients in the United States and other markets where resistant bacterial infections and difficult-to-treat infectious diseases represent significant healthcare challenges.View Spero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
